Physician profile
Gloria Arko Maguadog
NPI 1316105232
$13,763.45
in general payments reported to CMS, 2019-2025
25 companies · $4,638 in 2025
The $4,638 reported for 2025 was more than what 90% of Addiction Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $152).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.55 · 2023: $4,085 · 2024: $5,018 · 2025: $4,638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,381.16 |
| Education | $359.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,040.00 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $1,917.06 | 2023-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,786.87 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $1,459.02 | 2019-2025 | Aristada, Lybalvi |
| Indivior INC. | $887.81 | 2023-2025 | Perseris, Sublocade |
| Janssen Pharmaceuticals, INC | $845.50 | 2023-2025 | Invega Sustenna, Invega Trinza, Acclarent Aera |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $764.06 | 2023-2025 | Caplyta |
| Corium, LLC | $705.72 | 2023-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $652.73 | 2023-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $565.61 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $480.10 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $397.64 | 2024-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $265.40 | 2023-2024 | Jornay Pm |
| Tris Pharma INC | $224.96 | 2023-2025 | Onyda Xr, Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $199.17 | 2023-2025 | Trintellix |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $133.12 | 2025 | Qelbree |
| Merck Sharp & Dohme LLC | $109.74 | 2023 | Belsomra |
| Noven Therapeutics, LLC | $79.57 | 2024-2025 | Xelstrym, Secuado |
| Almatica Pharma LLC | $76.27 | 2025 | Loreev Xr |
| Harmony Biosciences LLC | $57.01 | 2023-2024 | Wakix |
| Collegium Pharmaceutical, INC. | $47.77 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $28.70 | 2023-2024 | Quviviq |
| Luye Pharma (USA) Ltd. | $18.83 | 2025 | Erzofri Extended-Release |
| Acadia Pharmaceuticals INC | $15.15 | 2024 | Nuplazid |
| Neuronetics, INC. | $5.64 | 2023 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gloria Maguadog listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.